热生物制剂
HTBX

From December 31, 2020 to December 31, 2021 ATM raise Issuance of common stock from vesting of restricted stock awards Cancellation and payout of fractional shares Issuance of restricted stock Exercise of options

From June 30, 2021 to September 30, 2021 Issuance of common stock from vesting of restricted stock awards

from December 31, 2020 to March 31, 2021 Issuance of common stock from vesting of restricted stock awards Issuance of restricted stock Exercise of options Cancellation and payout of fractional shares

from December 31, 2019 to December 31, 2020 January 2020 investment offering, net of underwriters discounts ATM raise Issuance of common stock from vesting of restricted stock awards Exercise of warrants Exchange of warrants

As a result of the Reverse Stock Split, every seven (7) shares of the Company’s issued and outstanding common stock prior to the Effective Time will be converted into one (1) share of common stock, reducing the number of issued and outstanding shares of the Company’s common stock from approximately 159.8 million to approximately 22.8 million. The Company’s transfer agent, Continental Stock Transfer & Trust Company (“Continental), will serve as exchange agent for the Reverse Stock Split and will provide instructions to stockholders of record regarding the process for exchanging shares.

From June 30, 2020 to September 30, 2020 ATM raise Exercise of warrants Exercise of options

From March 31, 2020 to June 30, 2020 ATM raise Exercise of warrants

From December 31, 2019 to March 31, 2020 January 2020 Investment offering, net of underwriters discounts ATM raise Issuance of common stock from vesting of restricted stock awards Exercise of warrants Exchange of warrants

1.Common stock offered by us 20,000,000 shares of our common stock. 2.The number of shares of common stock shown above to be outstanding after this offering is based on 37,420,652 shares outstanding as of January 16, 2020

from December 31, 2018 to December 31, 2019 Issuance of common stock from vesting of restricted stock awards, 1,201,555 shares

from December 31, 2018 to September 30, 2019 Issuance of common stock, 16,300 shares Stock-based compensation

from December 31, 2018 to June 30, 2019 Issuance of common stock, 16,300 shares Stock-based compensation

from December 31, 2018 to March 28, 2019 Stock-based compensation

from December 31, 2017 to December 31, 2018 Public offering, 14,375,000 shares, net of underwriters discounts Public offering, 9,200,000 shares, net of underwriters discounts Exercise of warrants, 3,054,667 shares Issuance of common stock, 1,566,997 Acquisition of non-controlling interest of Heat I/Pelican Stock-based compensation

from December 31, 2017 to September 30, 2018 Public offering, 14,375,000 shares, net of underwriters discount Exercise of warrants, 3,054,667 shares Issuance of common stock, 1,545,449 shares Stock-based compensation

From December 31, 2017 to June 30, 2018 Public offering, 14,375,000 shares, net of underwriters discount Exercise of warrants, 3,054,667 shares Issuance of common stock, 1,403,367 shares Stock-based compensation

From December 31, 2017 to March 28, 2018 Issuance of common stock, 1,403,367 shares Stock-based compensation

from December 31, 2016 to January 22,2018 Public offering, 575,000 shares, net of underwriters discounts Public offering, 620,650 shares, net of underwriters discounts Issuance of common stock, 234,858 shares Issuance of common stock for acquisition of Pelican, 133,106 shares Stock-based compensation Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, has announced a reverse stock split of its shares of common stock at a ratio of 1-for-10. The reverse stock split will take effect as of 11 p.m. ET, January 19, 2018. Shares of Heat common stock will trade on a post-split basis on the Nasdaq Capital Market under the existing trading symbol, "HTBX," at the market open on January 22, 2018.When the reverse stock split becomes effective, every 10 shares of the company's issued and outstanding common stock will be combined into one share of common stock. Effecting the reverse stock split will reduce the number of issued and outstanding common stock from approximately 42 million shares to approximately 4.2 million.

from December 31, 2016 to August 10, 2017 Public offering, 5,750,000 shares, net of underwriters discounts Issuance of common stock, 2,348,580 shares Issuance of common stock for acquisition of Pelican, 1,331,056 shares Stock-based compensation

from December 31, 2016 to June 30, 2017 Public offering, 5,750,000 shares, net of underwriters discounts Issuance of common stock, 2,346,727 shares Issuance of common stock for acquisition of Pelican, 1,331,056 shares Stock-based compensation

from December 31, 2016 to March 31, 2017 Public offering, 5,750,000 shares, net of underwriters discounts Issuance of common stock, 2,196,727 shares Stock-based compensation

from December 31, 2015 to December 31, 2016 Public offering, 9,100,000 shares, net of underwriters discounts Exercise of warrants, 3,863,429 shares Issuance of common stock, 4,791,377 shares Stock-based compensation

from December 31, 2015 to September 30, 2016 Public offering, 9,100,000 shares, net of underwriters’ discounts Exercise of warrants, 2,773,982 shares Issuance of common stock, 1,898,842 shares Stock-based compensation

from December 31, 2015 to March 31, 2016 Public offering, 9,100,000 shares, net of underwriters discounts

from December 31, 2014 to September 30, 2015 March 2015 public offering, 1,886,000 shares, net of underwriters discounts Vesting of restricted stock, 30,000 shares

from December 31, 2014 to May 11, 2015 March 2015 public offering, 1,886,000 shares net of underwriters discounts Vesting of restricted stock, 20,000 shares

From December 31, 2014 to March 27, 2015 March 2015 public offering, 1,886,000 shares net of underwriters discounts Vesting of restricted stock, 10,000 shares

From December 31, 2013 to December 31, 2014 Exercise of stock options, 66,707 shares Cashless exercise of warrants, 40,047 shares

from December 31, 2013 to September 30, 2014 Exercise of stock options, 55,837 shares Cashless exercise of warrants, 40,047 shares

from December 31, 2013 to June 30, 2014 Exercise of stock options, 55,837 shares Cashless exercise of warrants, 22,383 shares

from December 31, 2013 to March 31, 2014 Exercise of stock options, 54,532 shares Cashless exercise of warrants, 22,383 shares

From December 31,2012 to December 31,2013 March 25, 2013, 1,891,419 shares at $2.67 per share Preferred Series 1 Converted to Common Stock, July 29, 2013, 49,960Preferred Series A Converted to Common Stock, July 29, 2013, 810,057 Preferred Series B Converted to Common Stock, July 29, 2013, 836,666 Initial public offering, 2,700,000 shares, net of underwriting discounts Exercise of stock options, 80,706 shares

from December 31, 2012 to September 30, 2013 Issuance of Series B-1 Preferred Stock - March 25, 2013 Conversion of Preferred Stock into common stock Issuance of Common Stock from initial public offering, net of underwriting discounts Exercise of stock options

effected a 1-for-2.3 reverse stock split on May 29, 2013;the conversion of all outstanding shares of our convertible Preferred Stock and the accrued dividends thereof into an aggregate of 1,688,906 shares of our common stock which will occur automatically upon the closing of this offering;the issuance of an aggregate of 36,167 shares of common stock to the investors of our Series B-1 Preferred Stock, (having a value of $361,668 based on the initial public offering price of $10.00 per share), and which will occur automatically upon the closing of this offering.

from December 31, 2012 to May 29, 2013 March 25, 2013, 1,891,419 shares at $2.67 per share (unaudited) We effected a 1-for-2.3 reverse stock split of our outstanding common stock on May 29, 2013.

from December 31, 2011 to December 31, 2012 Preferred Stock Issued:March 7, 2012, 47,619 shares at $2.10 per share Preferred Stock Issued:April 3, 2012, 39,683 shares at $2.10 per share Preferred Stock Issued:April 27, 2012, 428,571 shares at $2.10 per share Common Stock Issued:December 31, 2012, 50,000 shares